Auro Vaccines
Clinical-stage vaccine development company focused on a prime/boost vaccine platform that tailors immune responses for prophylactic and therapeutic applications. The organization develops replication-competent RNA virus-vectored vaccines and plasmid DNA vaccine priming strategies (including plasmid-encoded molecular adjuvants and electroporation delivery), advances candidates through preclinical models and Phase 1 clinical testing, and collaborates with public- and private-sector partners. The company maintains an intellectual property estate and pursues out-licensing and partnership opportunities.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage filovirus (Ebola/Marburg) virus-vectored vaccine program
Replication-competent RNA virus-vectored filovirus vaccine candidates advanced to Phase 1 clinical evaluation and demonstrated protective efficacy in non-human primate challenge models; program has been out-licensed for further development.
Nipah/Hendra subunit vaccine (Phase I)
Subunit glycoprotein vaccine for Nipah/Hendra virus prevention advanced through IND-enabling studies, cGMP manufacture and currently in Phase I clinical evaluation.
Prophylactic vaccines poised for clinical evaluation (SARS-CoV-2, Chikungunya)
Vaccine candidates for SARS-CoV-2 and Chikungunya virus prepared for clinical entry, including virus-vectored constructs and supporting preclinical data.
Therapeutic HPV vaccine (clinical candidate)
Plasmid DNA prime followed by viral vector boost therapeutic vaccine candidate targeting multiple oncogenic HPV types to treat cervical dysplasia and associated cancers; candidate poised to enter clinical evaluation.
VesiculoVax™ Vaccines
Vesiculovirus vector vaccine technology designed for priming and boosting to induce rapid-onset immune protection against viral pathogens such as Ebola, Marburg, Lassa, and HIV-1.
VesiculoVax HIV gag vaccine
A recombinant vesicular stomatitis virus (rVSV) vectored HIV gag vaccine evaluated in first-in-human clinical evaluations.
Clinical-stage filovirus (Ebola/Marburg) virus-vectored vaccine program
Replication-competent RNA virus-vectored filovirus vaccine candidates advanced to Phase 1 clinical evaluation and demonstrated protective efficacy in non-human primate challenge models; program has been out-licensed for further development.
Nipah/Hendra subunit vaccine (Phase I)
Subunit glycoprotein vaccine for Nipah/Hendra virus prevention advanced through IND-enabling studies, cGMP manufacture and currently in Phase I clinical evaluation.
Prophylactic vaccines poised for clinical evaluation (SARS-CoV-2, Chikungunya)
Vaccine candidates for SARS-CoV-2 and Chikungunya virus prepared for clinical entry, including virus-vectored constructs and supporting preclinical data.
Therapeutic HPV vaccine (clinical candidate)
Plasmid DNA prime followed by viral vector boost therapeutic vaccine candidate targeting multiple oncogenic HPV types to treat cervical dysplasia and associated cancers; candidate poised to enter clinical evaluation.
VesiculoVax™ Vaccines
Vesiculovirus vector vaccine technology designed for priming and boosting to induce rapid-onset immune protection against viral pathogens such as Ebola, Marburg, Lassa, and HIV-1.
VesiculoVax HIV gag vaccine
A recombinant vesicular stomatitis virus (rVSV) vectored HIV gag vaccine evaluated in first-in-human clinical evaluations.
Services
Collaborative development, out-licensing and co-development of vaccine candidates and application of the prime/boost platform with pharmaceutical, biotechnology and public-sector partners.
Collaborative development, out-licensing and co-development of vaccine candidates and application of the prime/boost platform with pharmaceutical, biotechnology and public-sector partners.
Expertise Areas
- Vaccine platform development (prime/boost)
- Virus-vectored vaccine development
- Plasmid DNA vaccine design and delivery
- Preclinical immunology and animal challenge models
Key Technologies
- Recombinant attenuated negative-strand RNA viral vectors (rVSV-type)
- Plasmid DNA vaccines
- Plasmid-encoded molecular adjuvants (IL-12)
- In vivo electroporation delivery
News & Updates
Phase 1 randomized, double-blind, placebo-controlled clinical trial reporting safety and immunogenicity data for an attenuated rVSV-based Ebola GP vaccine.
Publication reporting safety and tolerability of multi-antigen plasmid DNA vaccine given with plasmid IL-12 via electroporation and boosted with recombinant vesicular stomatitis virus HIV Gag vaccine.
CEPI awarded funding to support development of a Nipah virus vaccine program.
Announcement of award/contract supporting development of multivalent vaccine for Ebola, Marburg and Lassa viruses.
Prototype virus-vectored vaccine demonstrated single-dose protection of non-human primates against lethal challenge with Ebola and Marburg viruses.
Phase 1 randomized, double-blind, placebo-controlled clinical trial reporting safety and immunogenicity data for an attenuated rVSV-based Ebola GP vaccine.
Publication reporting safety and tolerability of multi-antigen plasmid DNA vaccine given with plasmid IL-12 via electroporation and boosted with recombinant vesicular stomatitis virus HIV Gag vaccine.
CEPI awarded funding to support development of a Nipah virus vaccine program.
Announcement of award/contract supporting development of multivalent vaccine for Ebola, Marburg and Lassa viruses.
Prototype virus-vectored vaccine demonstrated single-dose protection of non-human primates against lethal challenge with Ebola and Marburg viruses.